Enhertu (trastuzumab deruxtecan) is an antibody pharmaceutical. Trastuzumab deruxtecan was first approved as Enhertu on 2019-12-20. It is used to treat breast neoplasms and gastrointestinal neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. It is known to target receptor tyrosine-protein kinase erbB-2.
|Common Name||Trastuzumab deruxtecan|
|Indication||breast neoplasms, gastrointestinal neoplasms|
|Drug Class||Monoclonal antibodies: humanized, tumors as target; antineoplastics (camptothecine derivatives)|